Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05504057 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Antihistamines, Amantadine and Evolution of COVID-19

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study title shortened, about 2 wordsv8
  2. Publications: 4 to 5v7
  3. Study completion date: Jun 13, 2025 to Feb 24, 2028
    • Secondary endpoints: 2 to 4
    • Study description expanded, about 3 words
    v6
  4. Enrollment target: 170000 to 140660
    • Primary completion date changed from estimate of Sep 30, 2024 to Jan 19, 2025
    • Publications: 3 to 4
    v5
  5. Re-verified, no change to tracked fieldsv4
Show 2 earlier versionsHide 2 earlier versions
  1. Primary completion date: Sep 30, 2022 to Sep 30, 2024v3
  2. Study title revisedv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.
Trial Details
NCT Number NCT05504057
Lead Sponsor Consorci Sanitari de Terrassa
Collaborators: Institut Català de la Salut
Conditions
(from sponsor)		 COVID-19
Related terms COVID-19
Enrollment 140,660 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov